Some compounds and molecules being investigated for targeting TC signaling pathways in CRC include PGE2 inhibitors, IL25 inhibitors, aryl hydrocarbon receptor (AHR) agonists and antagonists, Notch pathway inhibitors, and antibodies targeting TC markers [112,114,167,168,169,170,171,172,173,174]. This evidence concerns the gene AHR and colorectal carcinoma.